Showing Latest Articles
Large candidate gene association study reveals genetic risk factors and therapeutic targets for fibromyalgia
Arthritis & Rheumatism, 09/09/2011
Smith SB et al. – Variation in these genes may serve as a basis for development of new diagnostic approaches, and these genes' products may contribute to the pathophysiology of FM and represent potential targets for therapeutic action.
Methods- 496 FM patients included in the study as cases with total of 348 chronic pain-free controls
- Genotyping performed using dedicated gene array chip, the Pain Research Panel, which assays variants characterizing over 350 genes known to be involved in biological pathways relevant to nociception, inflammation, and mood
- Association testing was performed using logistic regression
- Significant differences in allele frequencies between cases and controls were observed for three genes: GABRB3 (rs4906902, p = 3.65x10-6), TAAR1 (rs8192619, p = 1.11x10-5) and GBP1 (rs7911, p = 1.06x10-4)
- 3 genes, and 7 other genes with suggestive evidence for association, were examined in second, independent cohort of FM patients and controls genotyped using the Perlegen 600K platform
- Evidence of association in replication cohort observed for TAAR1, RGS4, CNR1, and GRIA4 genes
